Name
GS2-01 - Trastuzumab deruxtecan vs physician's choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: Primary results of the randomized phase 3 study DESTINY-Breast02
Date & Time
Tuesday, December 6, 2022
Speakers
Virtual Session Link